Let’s Bring Great Science to Life: Reliable, Robust Solutions to Advance Your Analysis of Oligonucleotides
“At Agilent, innovation in emerging biopharma sciences like oligonucleotides is in our DNA. We are dedicated to partnering closely with customers like Vetter Pharma, providing them with exceptional workflow solutions that advance their oligonucleotide-based analysis.”
Mathieu Rault, Ph.D., global product manager, Agilent Technologies
Therapeutic Oligonucleotides Overview
Therapeutics oligonucleotides (oligos) have emerged as an area of particular interest and promise in biopharmaceutical development because of their potential to treat a wide range of diseases. These oligos can range in size, sequence complexity, and overall modifications. Synthetic oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs) and small interfering RNAs (si-RNAs), require thorough analysis to establish intended purity and quality.
Agilent Solutions
Advance Your Lead Oligonucleotide from Discovery to Market - Invest in a proven superior solution, services provider offering multi-application capabilities with a diverse compliant ready portfolio solution and world-class innovation to enable cost-effective manufacturing of commercial-scale quantities of synthetic oligonucleotides.
AGILENT OLIGONUCLEOTIDES END-TO-END WORKFLOW SOLUTIONS
Oligo Purity Analysis | Oligo Target Plus Impurity Analysis | Oligo Sequence Confirmation | Oligo Purification | Oligo Raw Material Identification | Trace Elemental Impurities | Residual Solvent Analysis | Oligo API Manufacturing
AGILENT OLIGONUCLEOTIDES WORKFLOW PRODUCTS
